Countervail announces the completion of an independent market analysis study for the company’s new Rapid Baseline-Free Organophosphate Exposure Diagnostic Test technology by Foresight Science & Technology, Inc.  The market research was done without influence from Countervail and included interviews with leading experts in the field, competition and regulatory review, and market opportunity assessment.  We are pleased to report that this independent market analysis supports the clear need and market opportunity for our novel diagnostic test currently under development.

Foresight Science & Technology, Inc. (Foresight), founded in 1980, is one of the world’s leading providers of commercialization, technology transfer, and due diligence services.  Members of the Foresight team are veterans of commercialization and product development with experience in research, technology transfer, licensing, new venture creation, and business development.

The market analysis study was supported by the National Institutes of Health via the new Niche Assessment Program and awards were limited to 200 SBIR/STTR Phase I awardees that applied.